Overview

Singular Genomics focuses on advancing the field of genomics, which involves studying the complete set of DNA in organisms. The company provides tools and technologies for genomic sequencing, helping clients like academic researchers, pharmaceutical companies, and clinical laboratories conduct multiomic research. This type of research examines various biological data, including DNA, RNA, and proteins, to gain insights into complex biological systems and diseases. Singular Genomics' main product is the G4 sequencing platform, which allows for ultra-high throughput and high-resolution spatial sequencing, enabling researchers to process multiple samples at once. This efficiency sets Singular Genomics apart from competitors in the genomics market. The company's goal is to support scientific and medical research by offering high-performance sequencing technologies that aid in understanding and treating complex diseases.

Simplify's Take

What believers are saying

• The acquisition by Deerfield Management provides financial backing and strategic insight.
• Growing demand for personalized medicine aligns with Singular Genomics' high-resolution sequencing focus.
• The increasing use of multiomics approaches supports Singular Genomics' integrated platform solutions.

What critics are saying

• Increased competition from Illumina and Element Biosciences may impact market share.
• Rapid technological advancements could render current platforms obsolete without quick innovation.
• Regulatory scrutiny on genomic data privacy could increase compliance costs.

What makes Singular Genomics unique

• Singular Genomics offers a unique multiomics solution with its PX Integrated Solution.
• The G4 Sequencing Platform provides ultra-high throughput and high-resolution spatial sequencing.
• Singular Genomics' partnership with Fluent Biosciences enhances scalable single-cell RNA sequencing.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$303.6M

Above

Industry Average

Funded Over

2 Rounds

Notable Investors:

Coatue Management

Notable Investors:

Coatue Management

$258,100,000

IPO

May 2021

IPO funding comparison data is currently unavailable. We're working to provide this information soon!

IPO Funding Comparison

Coming Soon

View all funding stages

Stock Price